04/04/19 | Watch your "stem cell" wording - On going FBI investigations

For those offices that are using the wording 'stem cells' or charging patients for these services you need to be aware of the FBI ongoing investigations.

Watch your
02/28/19 | Great article on the issues with 63047 and 22633 and 22630

Find out about the issues between 22633/22630 and 63047 and get the history of these codes.  Great information you can use for your private payer appeals.

Great article on the issues with 63047 and 22633 and 22630
01/02/19 | Accessing Newsletters

How to get newsletters

Accessing Newsletters
01/02/19 | Calendar events

Calendar events

Calendar events
09/26/18 | Scam audio flyer Fionexia - please don't sign up

It has come to my attention that there is a flyer (from Fionexia) that is going out from a company that is fraudualent and stating I am doing an audio for them.  Please do not sign up it is a scam.  The audio they are advertising was done for AudioEducator.com. It appears if you pay for it you may not get anything for your pay!!!

Scam audio flyer Fionexia - please don't sign up
08/11/18 | Margie Vaught Newsletters

Now you can access and download the newsletters directly from this site. 

Margie Vaught Newsletters
07/20/18 | 2019 Proposed Fee schedule released

Proposed 2019 Fee Schedule is out – hang on to your seats…

CMS released the 12th of July the proposed changed for the physician fee schedule for 2019 (https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2018-Press-releases-items/2018-07-12.html).

2019 Proposed Fee schedule released
07/20/18 | CPT updates policy of 63047 with 22633

CPT updates their policy regarding nerve root decompressions and interbody fusions

AANS, NASS and AAOS have been working hard on getting CPT to change their previous October 2016 CPT Assistant regarding nerve root decompression 63047 and interbody fusion 22633 being inclusive

CPT updates policy of 63047 with 22633
Archive - See All Entries


April 4, 2019  

 Attorney General’s Press Office/ 212-416-8060 nyag.pressoffice@ag.ny.gov 

 Attorney General James Announces Lawsuit Against New York City Stem Cell Clinic for Scamming Vulnerable Patients Out Of Thousands 

 Park Avenue Stem Cell Deceived New Yorkers Into Paying Thousands of Dollars For Unproven And Potentially Harmful Stem Cell Procedures  

 NEW YORK —Attorney General Letitia James today announced a lawsuit filed against Park Avenue Stem Cell, a New York City for-profit stem cell clinic, and its managing doctor, Dr. Joel B. Singer, M.D., for allegedly engaging in fraudulent and illegal advertising regarding its stem cell procedures.   

Through advertising efforts, the clinic led vulnerable patients to believe it could treat a variety of serious medical conditions using the patients’ own stem cells, including, but not limited to: urological diseases, erectile dysfunction, cardiac/pulmonary disease, neurological diseases such as Parkinson’s disease and ALS, various autoimmune diseases such as lupus, and orthopedic conditions. While stem cells hold promise for future use, there is currently no adequate scientific substantiation that stem cells can effectively treat any of these conditions.  Despite this, the Defendants charged consumers nearly $4,000 per procedure, with many consumers paying for multiple procedures. 

“Misleading vulnerable consumers who are desperate to find a treatment for serious and painful medical conditions is unacceptable, unlawful, and immoral,” said Attorney General Letitia James. “We will continue to investigate these types of clinics that shamelessly add to the suffering of these consumers by charging them thousands of dollars for treatments that they know are unproven.” 

The complaint also alleges that Defendants misrepresented that their procedures were FDA-approved, that their patients are participating in an established research study, and that their procedures have been endorsed by several scientific and medical organizations.  

In the United States, stem cell products are regulated by the Food and Drug Administration (“FDA”).  Currently, the only stem cell-based products that have been approved by the FDA are blood-forming stem cells derived from cord-blood, which have been approved for limited use. Instead, the defendants, used stem cells obtained from the patient’s own adipose tissue, commonly known as fat, for a wide range of conditions.  

Until at least late 2018, Park Avenue Stem Cell was affiliated with the Cell Surgical Network, a California corporation that was sued by the FDA in May 2018 for allegedly administering stem cell products that were adulterated or misbranded and not approved. The FDA seeks a permanent injunction against the corporation, a related entity and their two main doctors.  As an affiliate, Park Avenue Stem Cell followed the protocols prescribed by CSN. 

For more information on important factors to consider when evaluating stem cell therapies, visit the FDA website

This case is being handled by Special Counsel Mary Alestra, under the supervision of Deputy Bureau Chief Laura J. Levine and Bureau Chief Jane M. Azia, all of the Consumer Frauds and Protection Bureau.  The Consumer Frauds and Protection Bureau is overseen by Executive Deputy Attorney General of Economic Justice Christopher D’Angelo.